HRTIS.HE

Herantis Pharma Oyj [HRTIS.HE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HRTIS.HE Stock Summary

Top 10 Correlated Stocks

HRTIS.HE

In the News

HRTIS.HE Financial details

Company Rating
-
Market Cap
28.22M
Income
-3.39M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
06 Mar 2024
P/E
-2.2
Forward P/E
-
PEG
0.35
P/S
-
P/B
-3.89
P/C
-
P/FCF
-0.04
Quick Ratio
3.15
Current Ratio
3.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.27
EPS next Y
-
EPS next Q
-
EPS this Y
-102.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-209.09%
-
-
-
-
SMA20
1.44%
SMA50
-4.73%
SMA100
10.16%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
297%
ROC
-0.02%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.17-2.32
52W High
-32%
52W Low
+36%
RSI
42.04
Rel Volume
0.94
Avg Volume
7.16K
Volume
6.74K
Perf Week
-6.21%
Perf Month
-2.86%
Perf Quarter
-2.86%
Perf Half Y
-4.9%
-
-
-
-
Beta
0.308
-
-
Volatility
0.04%, 0.03%
Prev Close
0.74%
Price
1.36
Change
-4.23%

Something similar

Top by Market Cap
3V64.DE
BRYN.DE
AMZN
EMBASSY.NS
MSF.DE
Same Sector
ALT
STTK
603538.SS
SPOK
GBLX
Top Correlated Stocks
0894.HK
Similar Market Cap
WYLD.ST
8475.HK
2122.HK
FHQ.TO
VVO.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 7.16K
  • Market Capitalization 28.22M
  • Employee 10
  • CEO Dr. Antti Vuolanto D.Sc. (Tech)
  • Headquarters Espoo,FI
  • IPO Date 2014-06-11
  • Website https://www.herantis.com

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.